Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer

Next Previous
X
Search
Trial Profile

A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 24 Sep 2020 The phase 2 study was terminated early due to poor accrual, according to results published in the BJU International.
    • 24 Sep 2020 Results published in the BJU International.
    • 16 Feb 2019 Results of pooled analysis of phase 1/2 study assessing safety and efficacy of cabozantinib plus docetaxel and prednisone versus docetaxel and prednisone alone in metastatic castrate-resistant prostate cancer presented at the 2019 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top